Incyte (INCY) Profit After Tax (QoQ) (2010 - 2026)

Incyte (INCY) Profit After Tax (QoQ) (2010 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Incyte 23.64 Bn 19.62 Bn 1.17 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.35%
Dec 31, 2025 -29.44%
Sep 30, 2025 4.73%
Jun 30, 2025 156.00%
Mar 31, 2025 -21.37%
Dec 31, 2024 89.01%
Sep 30, 2024 123.94%
Jun 30, 2024 -362.23%
Mar 31, 2024 -15.68%
Dec 31, 2023 17.41%
Sep 30, 2023 -15.86%
Jun 30, 2023 837.88%
Mar 31, 2023 -23.74%
Dec 31, 2022 -74.76%
Sep 30, 2022 -30.14%
Jun 30, 2022 324.91%
Mar 31, 2022 -93.26%
Dec 31, 2021 210.25%
Sep 30, 2021 21.60%
Jun 30, 2021 179.17%